Skip to main content
Top

Current Oncology Reports

Issue 5/2012

Content (14 Articles)

Leukemia (A Aguayo, Section Editor)

Acute Myeloid Leukemia with Normal Cytogenetics

Raya Mawad, Elihu H. Estey

Leukemia (A Aguayo, Section Editor)

Diagnosis of Acute Leukemia in Cerebrospinal Fluid (CSF-Acute Leukemia)

Erick Crespo-Solis, Xavier López-Karpovitch, Jesús Higuera, Beatriz Vega-Ramos

Leukemia (A Aguayo, Section Editor)

Chronic Myeloid Leukemia: State of the Art in 2012

Carmen Fava, Giovanna Rege-Cambrin, Giuseppe Saglio

Leukemia (A Aguayo, Section Editor)

Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options

Theresa Liu-Dumlao, Hagop Kantarjian, Deborah A. Thomas, Susan O’Brien, Farhad Ravandi

Lymphomas (PA Hamlin, Section Editor)

NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm

Ritsuro Suzuki

Lymphomas (PA Hamlin, Section Editor)

B-Cell Receptor Pathobiology and Targeting in NHL

Ines M. Macias-Perez, Ian W. Flinn

Lymphomas (PA Hamlin, Section Editor)

Novel Agents in Hodgkin Lymphoma

Alison J. Moskowitz

Lymphomas (PA Hamlin, Section Editor)

Transformation in Follicular Lymphoma: Biology, Prognosis, and Therapeutic Options

Eric Wong, Michael Dickinson

Lymphomas (PA Hamlin, Section Editor)

Active Immunotherapy: Current State of the Art in Vaccine Approaches for NHL

M. Lia Palomba

Melanoma (K Margolin, Section Editor)

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

Michael A. Postow, Omid Hamid, Richard D. Carvajal

Melanoma (K Margolin, Section Editor)

Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies

Janice M. Mehnert, Harriet M. Kluger

Melanoma (K Margolin, Section Editor)

Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?

Clara Curiel-Lewandrowski, Suephy C. Chen, Susan M. Swetter

Melanoma (K Margolin, Section Editor)

Tumor-Infiltrating Lymphocytes in Melanoma

Sylvia Lee, Kim Margolin

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine